Success Metrics

Completion Rate
0%(0/1)
Active Trials
2(33%)
Terminated
1(17%)

Phase Distribution

Ph phase_2
4
67%
Ph phase_1
2
33%

Phase Distribution

2

Early Stage

4

Mid Stage

0

Late Stage

Phase Distribution6 total trials
Phase 1Safety & dosage
2(33.3%)
Phase 2Efficacy & side effects
4(66.7%)

Highest Phase Reached

Phase 2

Trial Status & Enrollment

Completion Rate

0.0%

0 of 1 finished

Non-Completion Rate

100.0%

1 ended early

Currently Active

2

trials recruiting

Total Trials

6

all time

Status Distribution
Active(5)
Terminated(1)

Detailed Status

Not yet recruiting3
Recruiting2
Terminated1

Development Timeline

Analytics

Development Status

Total Trials
6
Active
2
Success Rate
0.0%
Most Advanced
Phase 2

Trials by Phase

Phase 12 (33.3%)
Phase 24 (66.7%)

Trials by Status

recruiting233%
terminated117%
not_yet_recruiting350%

Recent Activity

2 active trials
Showing 5 of 6
terminatedphase_1

A Phase I Clinical Study of Recombinant Humanized Anti-BTLA Monoclonal Antibody (JS004) Injection Combined With Toripalimab Injection in Patients With Advanced Solid Tumors

NCT05427396
recruitingphase_2

Combination of Toripalimab and JS004 Therapy for ccRCC

NCT06690697
not_yet_recruitingphase_2

Toripalimab and JS004 Combined With Platinum-based Chemotherapy for Relapsed and Extensive-stage Small Cell Lung Cancer

NCT06648200
recruitingphase_2

Neoadjuvant Therapy With Toripalimab and JS004 Combined With Etoposide and Platinum Chemotherapy for Limited-stage Small Cell Lung Cancer : A Phase 2 Trial

NCT06256237
not_yet_recruitingphase_1

Newly Emerging Immunotherapy for Pancreatic Cancer Treatment

NCT06370754
View all 6 trials

Clinical Trials (6)

Showing 6 of 6 trials
NCT05427396Phase 1

A Phase I Clinical Study of Recombinant Humanized Anti-BTLA Monoclonal Antibody (JS004) Injection Combined With Toripalimab Injection in Patients With Advanced Solid Tumors

Terminated
NCT06690697Phase 2

Combination of Toripalimab and JS004 Therapy for ccRCC

Recruiting
NCT06648200Phase 2

Toripalimab and JS004 Combined With Platinum-based Chemotherapy for Relapsed and Extensive-stage Small Cell Lung Cancer

Not Yet Recruiting
NCT06256237Phase 2

Neoadjuvant Therapy With Toripalimab and JS004 Combined With Etoposide and Platinum Chemotherapy for Limited-stage Small Cell Lung Cancer : A Phase 2 Trial

Recruiting
NCT06370754Phase 1

Newly Emerging Immunotherapy for Pancreatic Cancer Treatment

Not Yet Recruiting
NCT05891080Phase 2

Neoadjuvant Therapy With Toripalimab and JS004 Combined With Platinum-based Doublet Chemotherapy for Resectable or Potentially Resectable Stage III Non-small Cell Lung Cancer: A Randomised Controlled, Open-label, Phase 2 Trial

Not Yet Recruiting

All 6 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
6